智通财经网·2026-01-08 07:50Core Insights - JD Health has formed a deep collaboration with local innovative pharmaceutical company Kaiqi Xincheng Biopharmaceutical Technology Co., Ltd. to support the clinical cure of chronic hepatitis B patients in China [1][2] - The collaboration will leverage JD Health's strengths in medical services and instant retail, launching two innovative drugs: the first-class drug Adefovir Dipivoxil Tablets (brand name: Xinshumu®) and a zinc-selenium multivitamin soft capsule (brand name: Kaimumu®) [1][2] Drug Launch Details - Adefovir Dipivoxil Tablets (Xinshumu®) are designed for the treatment of adult chronic hepatitis B and have received support from national major new drug creation technology projects during the "12th Five-Year" and "13th Five-Year" plans [1] - Clinical trial results indicate that the drug effectively and persistently inhibits the virus, with a significantly higher proportion of patients achieving HBsAg levels below 1000 IU/mL compared to the control group (P<0.05) and other similar drugs [1] - The zinc-selenium multivitamin soft capsule (Kaimumu®) is formulated for liver nutrition and is rich in nine vitamins and two minerals, designed for easy absorption and convenient daily use [2] Service Integration - JD Health will utilize its ecosystem of "online consultation + pharmaceutical retail + instant delivery" to create a service loop that includes professional supply, online specialist guidance, and rapid delivery, facilitating the widespread availability of the new drugs [2] - Patients can purchase these new drugs through the JD APP or JD pharmacies nationwide with a valid prescription starting immediately [2] Strategic Goals - JD Health aims to enhance the overall efficiency and quality of the pharmaceutical supply chain through ongoing strategic collaboration with Kaiqi Xincheng, optimizing the patient experience [2] - The company is committed to providing high-quality pharmaceutical health products and services, contributing to the "Healthy China 2030" strategic goals by improving the accessibility of innovative drugs [3]